Proof-of Principle Study Finds Imatinib Improves Symptoms for Patients with Severe Asthma
In a new, proof-of-principle study, researchers found that targeting the mast cells with imatinib, a drug used to effectively treat certain forms of cancer, improved airway hyper responsiveness, and decreased the number of mast cells present. (Source: BWH News)
Source: BWH News - May 17, 2017 Category: Hospital Management Source Type: news
Novartis misses on rev, tops sales estimates in Q1
Shares in Novartis (NYSE:NVS) rose today after the pharmaceutical company met expectations on Wall Street with its 1st quarter earnings, but missed on sales largely thanks to growing pressure from generics to the company’s top-selling chemotherapy, Gleevec.
The company posted profits of $1.92 billion, or 22¢ per share, on sales of $11.53 billion for the 3 months ended March 31, for bottom-line loss of -22% on sales loss of -1% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartis misses on rev, tops sales estimates in Q1 appeared first on MassD...
Source: Mass Device - April 25, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: MassDevice Earnings Roundup Optical/Ophthalmic Pharmaceuticals Wall Street Beat Novartis Source Type: news
KIT Mutations Linked to Imatinib Response in GIST KIT Mutations Linked to Imatinib Response in GIST
Different KIT mutations have various associations with the response of gastrointestinal stromal tumors (GISTs) to adjuvant imatinib, according to results from a Scandinavian Sarcoma Group multicenter trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news
TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension. (Source: CancerNetwork)
Source: CancerNetwork - March 29, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Gleevec - A Game Changer?
(MedPage Today) -- The drug has improved survival for the majority of CML patients (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 22, 2017 Category: American Health Source Type: news
New England Journal of Medicine publishes long-term results of Gleevec ®
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML. The New England Journal of Medicine has published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. (Source: World Pharma News)
Source: World Pharma News - March 10, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Leukemia drug fends off cancer for a decade, study shows
Gleevec, the brand name for imatinib, "has stood the test of time" with no new safety risks, say cancer experts (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 9, 2017 Category: Consumer Health News Source Type: news
Long-term results of Gleevec ® published
Results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent, have now been published by investigators. According to the National Cancer Institute, prior to Gleevec ' s 2001 FDA approval, fewer than one in three CML patients survived five years past diagnosis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 9, 2017 Category: Science Source Type: news
' Imatinib Changed Everything': The Future Is Now More Hopeful'Imatinib Changed Everything': The Future Is Now More Hopeful
The development in the 1990s of this oral drug that targets a driver mutation ' fundamentally altered the field of oncology, ' says an NEJM editorial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 9, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Title: Gleevec Keeps a Leukemia in Check for More Than a Decade: StudyCategory: Health NewsCreated: 3/8/2017 12:00:00 AMLast Editorial Review: 3/9/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 9, 2017 Category: Cancer & Oncology Source Type: news
Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there's no evidence of safety concerns linked to long-term use of the drug, researchers say (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - March 9, 2017 Category: Cancer & Oncology Source Type: news
Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there ' s no evidence of safety concerns linked to long - term use of the drug, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 8, 2017 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, News, Source Type: news
' Imatinib Changed Everything' (CME/CE)
(MedPage Today) -- Legacy confirmed by long-term data from pivotal trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 8, 2017 Category: Hematology Source Type: news
Final Results of Landmark Imatinib Study in CML Show Long-Term Benefit
The final, long-term analysis of the landmark IRIS study showed that imatinib ’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
